30
total announcements
ASTRAZEN.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 19 Oct 2026
Market Cap
₹14,830 Cr
P/E (TTM)
87.4
EPS (TTM)
₹67.85
52W Low
₹5,640.00
52W High
₹9,849.50
Dividend Yield
0.60%
Beta
0.23
Price / Book
17.0
Debt / Equity
12.7
Revenue (TTM)
₹2,432 Cr
Gross Margin
36.83%
Operating Margin
6.40%
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and distribute Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for an additional indication in India.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Dividend'. The company has sent an email communication to its shareholders regarding the deduction of tax at source on Dividend for the financial year 2025-26. The dividend will be paid after deducting tax at source under section 393 of the Income Tax Act, 2025. Resident shareholders with a total dividend amount to be paid in FY 27 not exceeding INR 10,000 will not have tax deducted at source. Tax will be deducted at 10% for resident shareholders not meeting the eligibility conditions, and 20% for non-resident shareholders.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about the dispatch of notice of the 47th Annual General Meeting (AGM) and e-voting information.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has announced a record date of July 31, 2026, for determining the entitlement of members eligible for the payment of a final dividend for the financial year 2025-26.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the financial year ended March 31, 2026'. The report includes details of the company's sustainability initiatives, governance, and financial performance.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026. The meeting will be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM) to transact the following business: to receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon. Other agenda items include the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director, the declaration of a dividend of Rs. 36/- per share on equity shares for the financial year 2025-26, and the appointment of a Director in place of Ms. Bhavana Agrawal (DIN: 10485441) who retires by rotation.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization to import and market Benralizumab 30 mg/ml solution for injection in pre-filled syringe (Fasenra) for an additional indication, Hypereosinophilic Syndrome (HES) in patients aged 12 years and older.
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited has informed the Exchange about the appointment of Senior Management Personnel (SMP) as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The appointments include Mr. Mihir Parikh as Director - Commercial Excellence, BD & Strategy, Mr. Vinay Sharma as Director - Rare Diseases Business Unit, and Mr. Amay Ashok Pandey as Director – Oncology Business Unit.